Healy Sees Changes Ahead For NIH; Massey Backs NSF Agenda

NIH's new director isn't shy about stating her agency's needs, while NSF's new leader likes things the way they are WASHINGTON--Bernadine Healy, the new director of the National Institutes of Health, wants to shake things up. Walter Massey, the new director of the National Science Foundation, hopes to stay the course. If both wishes are fulfilled, scientists may see NIH becoming more active on a variety of issues, such as managing research dollars and promoting women, and NSF continuing to p

Written byJeffrey Mervis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

WASHINGTON--Bernadine Healy, the new director of the National Institutes of Health, wants to shake things up. Walter Massey, the new director of the National Science Foundation, hopes to stay the course. If both wishes are fulfilled, scientists may see NIH becoming more active on a variety of issues, such as managing research dollars and promoting women, and NSF continuing to promote large interdisciplinary centers and projects with potential economic payoffs.

Last month, in separate public appearances two days apart, the new heads of the federal government's leading basic research agencies signaled different approaches to running their organizations. Healy, a cardiologist who directed the research institute at the Cleveland Clinic Foundation, offered her views during her confirmation hearing before the Senate Labor and Human Services Committee. They were her first public statements on biomedical policy since being named last fall as the Bush administration's choice to succeed James Wyngaarden. She was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies